← Back to feed

Isomorphic Labs has closed a $2.1 billion Series B, converting the round that was reported in negotiations earlier this year into committed capital. The raise is led by Thrive Capital, with Alphabet and GV participating as existing backers alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.

The Company

Isomorphic Labs was founded in 2021 as a spin-out of DeepMind, led by CEO Demis Hassabis and President Max Jaderberg. The company’s core product is IsoDDE — the Isomorphic Drug Design Engine — a suite of AI models trained for structure prediction, binding affinity scoring, and generative molecule design across multiple therapeutic areas and drug modalities.

The public-facing anchor of IsoDDE is AlphaFold-derived protein structure work, but the internal system extends well beyond static structure prediction. Isomorphic has described IsoDDE as capable of navigating novel biological systems with accuracy sufficient for real drug-candidate generation, not just academic benchmarking. It is advancing both partner programs and wholly-owned internal programs toward the clinic.

What the Capital Does

Three stated uses: develop and deploy IsoDDE further, advance its drug candidate pipeline toward clinical trials, and hire across AI research, engineering, drug design, and clinical functions globally. The company operates from London headquarters with offices in Cambridge, Massachusetts and Lausanne, Switzerland.

The Hassabis quote in the announcement is calibrated: “we have shown our approach is fundamentally sound.” That phrasing signals the company has internal validation it is not yet publishing — program progression data or binding results it considers reproducible but pre-publication.

Investor Composition

The investor mix tells a clearer story than the headline number. Thrive Capital leads a round that includes:

• Alphabet and GV (existing, Google’s corporate and venture arms)
• MGX (Abu Dhabi state-backed technology investor)
• Temasek (Singapore sovereign wealth fund)
• CapitalG (Alphabet’s independent growth fund, separate from GV)
• UK Sovereign AI Fund (new government-backed AI vehicle)

Three sovereign or quasi-sovereign funds in one round is unusual. It positions Isomorphic not only as a biotech investment but as strategic infrastructure — the kind of asset that governments with no domestic frontier AI drug platform want exposure to.

The Competitive Context

The AI drug discovery market has consolidated toward three approaches: pure-play AI-native companies like Isomorphic, large pharma adopting AI tooling internally, and academic spin-outs. Isomorphic occupies the most defensible position: access to DeepMind compute and research talent, a CEO who has won the Nobel Prize in Chemistry for the AlphaFold work, and a $2.1B runway that extends its lead before the 2027-2028 window when most competitors expect their first clinical readouts.

The closest competitive surface is not another AI company — it is the internal AI infrastructure buildouts at Pfizer, Roche, and AstraZeneca, each of which has committed over $1B to AI drug design since 2024. Isomorphic’s pitch is that its models outperform internally built alternatives because the depth of training at DeepMind’s compute scale cannot be replicated by pharma IT budgets alone.